Literature DB >> 21256094

A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study.

Liping Tong1, Likun Ding, Yan Li, Zhirui Wang, Jingwen Wang, Yu Liu, Lin Yang, Aidong Wen.   

Abstract

A sensitive and rapid LC-MS/MS method was developed and validated for the determination of levamisole in human plasma. The assay was based on liquid-liquid extraction of analytes from human plasma with ethyl ether. Chromatographic separation was carried on an Agilent HC-C(8) column (150 mm × 4.6 mm, 5 μm) at 40°C, with a mobile phase consisting of acetonitrile-10 mM ammonium acetate (70:30, v/v), a flow rate of 0.5 mL/min and a total run time of 6 min. Detection and quantification were performed by mass spectrometry in the multiple reaction monitoring mode with positive electrospray ionization m/z at 205.1→178.2 for levamisole, and m/z 296.1→264.1 for mebendazole (internal standard). The assay was linear over a concentration range of 0.1-30 ng/mL with a lower limit of quantification of 0.1 ng/mL. The coefficient of variation of the assay precision was less than 8.5%. The assay was successfully used to analyze human plasma samples in a pharmacokinetic study where levamisole was administered as a liniment.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21256094     DOI: 10.1016/j.jchromb.2010.11.015

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  A R Kreeftmeijer-Vegter; T P C Dorlo; M P Gruppen; A de Boer; P J de Vries
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

2.  Development of RP-HPLC Method for the Simultaneous Quantitation of Levamisole and Albendazole: Application to Assay Validation.

Authors:  S Sowjanya; Ch Devadasu
Journal:  Int J Anal Chem       Date:  2018-07-02       Impact factor: 1.885

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.